The Appearance of Cardiac Metastasis From Squamous Cell Carcinoma of the Lung on F-18 FDG PET/CT and Post Hoc PET/MRI

Probst, Stephan; Seltzer, Alexandra; Spieler, Bradley; Chachoua, Abraham; Friedman, Kent

doi:10.1097/rlu.0b013e31820a9fd1

Cited by 9 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 ). Probst et al reported the beneficial use of PET/MR in a patient with squamous cell carcinoma of lung with metastasis to the cardiovascular system [ 18 ]. Recently, whole-body MR diffusion-weighted imaging has been used in oncology.…”

Section: Cardiac Massesmentioning

confidence: 99%

Incremental value of PET and MRI in the evaluation of cardiovascular abnormalities

et al. 2016

View full text Add to dashboard Cite

The cardiovascular system is affected by a wide range of pathological processes, including neoplastic, inflammatory, ischemic, and congenital aetiology. Magnetic resonance imaging (MRI) and positron emission tomography (PET) are state-of-the-art imaging modalities used in the evaluation of these cardiovascular disorders. MRI has good spatial and temporal resolutions, tissue characterization and multi-planar imaging/reconstruction capabilities, which makes it useful in the evaluation of cardiac morphology, ventricular and valvar function, disease characterization, and evaluation of myocardial viability. FDG-PET provides valuable information on the metabolic activity of the cardiovascular diseases, including ischemia, inflammation, and neoplasm. MRI and FDG-PET can provide complementary information on the evaluation of several cardiovascular disorders. For example, in cardiac masses, FDG-PET provides the metabolic information for indeterminate cardiac masses. MRI can be used for localizing and characterizing abnormal hypermetabolic foci identified incidentally on PET scan and also for local staging. A recent advance in imaging technology has been the development of integrated PET/MRI systems that utilize the advantages of PET and MRI in a single examination. The goal of this manuscript is to provide a comprehensive review on the incremental value of PET and MRI in the evaluation of cardiovascular diseases.Main Messages• MRI has good spatial and temporal resolutions, tissue characterization, and multi-planar reconstruction• FDG-PET provides valuable information on the metabolic activity of cardiovascular disorders• PET and MRI provide complementary information on the evaluation of cardiovascular disordersElectronic supplementary materialThe online version of this article (doi:10.1007/s13244-016-0494-5) contains supplementary material, which is available to authorized users.

show abstract

Section: Cardiac Massesmentioning

confidence: 99%

Incremental value of PET and MRI in the evaluation of cardiovascular abnormalities

et al. 2016

View full text Add to dashboard Cite

show abstract

“…A single older case history of cardiac metastasis in a patient with squamous epithelial cancer of the lung demonstrates the use of post-hoc fused PET-MRI [29]. A study of the differentiation of benign and malignant cardiac tumors using FDG PET/CT showed high diagnostic accuracy (sensitivity 100 %, specificity 86 %) compared to the histopathological reference standard [30].…”

Section: Cardiac Tumorsmentioning

confidence: 99%

Cardiovascular Hybrid Imaging using PET/MRI

Nensa¹,

Schlosser²

2014

Fortschr Röntgenstr

View full text Add to dashboard Cite

!The following overview provides a summary of the state of the art and research as well as potential clinical applications of cardiovascular PET/MR imaging. PET/MRI systems have been clinically available for a few years, and their use in cardiac imaging has been successfully demonstrated. At this period in time, some of the technical difficulties that arose at the beginning have been solved; in particular with respect to MRI-based attenuation correction, caution should be exercised with PET quantification. In addition, many promising technical options are still in the developmental stage, such as MRI-based motion correction of PET data resulting from simultaneous MR acquisition, and are not yet available for cardiovascular imaging. On the other hand, PET/MRI has been used to demonstrate significant pathologies such as acute and chronic myocardial infarction, myocarditis or cardiac sarcoidosis; future applications in clinical routine or within studies appear to be possible. In coming years additional studies will have to be performed to prove diagnostic gain at a reasonable cost-benefit ratio before valid conclusions are possible regarding the clinical utility and future of cardiovascular PET/MR imaging.

show abstract